Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407977 · ClinicalTrials.gov registry record
Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 13
- Enrollment target
NCT02407977: Completed study, sponsored by Duke University.
NCT02407977 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02407977 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
This is an observational study. This protocol will determine the feasibility of using a novel nano-material based fiber-optic dosimeter (nanoFOD) device, with dimensions less than 1 mm wide, to measure real-time, pin-point, in-vivo radiation dose given during external beam delivery of radiation therapy treatments.This new protocol is similiar in design to Pro00050297 with the significant difference being the monitoring will be performed during external baem radiotherapy.
Interventions
- OTHER Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-11-13 |
| Est. Completion | 2017-04-19 |
What the finished NCT02407977 record still lists
NCT02407977 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD) is the first listed.
NCT02407977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02407977 about?
NCT02407977 is a clinical study titled "Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy". This is an observational study. This protocol will determine the feasibility of using a novel nano-material based fiber-optic dosimeter (nanoFOD) device, with dimensions less than 1 mm wide, to measure real-time, pin-point, in-vivo radiation dose given during external beam delivery of radiation ther...
What is the current status of trial NCT02407977?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2015-11-13. Estimated completion is 2017-04-19.
What interventions are being tested in trial NCT02407977?
The interventions under investigation include: Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD) (OTHER).
Who is sponsoring clinical trial NCT02407977?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI